Spero Therapeutics Tech Stack

Spero Therapeutics uses 8 technology products and services including IBM Cognos Analytics, Drupal, Google Charts, and more. Explore Spero Therapeutics's tech stack below.

  • IBM Cognos Analytics
    Advanced Analytics And Data Science
  • Drupal
    Content Management System
  • Google Charts
    Javascript Graphics
  • prettyPhoto
    Javascript Libraries
  • Microsoft
    Miscellaneous
  • Webflow
    Page Builders
  • Yoast SEO
    Search Engines
  • Nginx
    Web Servers

Media & News

Spero Therapeutics's Email Address Formats

Spero Therapeutics uses at least 4 format(s):
Spero Therapeutics Email FormatsExamplePercentage
flast@sperotherapeutics.comJDoe@sperotherapeutics.com
91%
first@sperotherapeutics.comJohn@sperotherapeutics.com
6%
firstl@sperotherapeutics.comJohnD@sperotherapeutics.com
2%
first-last@sperotherapeutics.comJohn-Doe@sperotherapeutics.com
1%

Frequently Asked Questions

Where is Spero Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Spero Therapeutics's main headquarters is located at 675 Massachusetts Ave 14th Floor Cambridge, MA 02139 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Spero Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Spero Therapeutics's main corporate office by phone at +1-857-242-1600. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Spero Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Spero Therapeutics is a publicly traded company; the company's stock symbol is SPRO.

What is Spero Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Spero Therapeutics's official website is sperotherapeutics.com and has social profiles on LinkedIn.

How much revenue does Spero Therapeutics generate?

Minus sign iconPlus sign icon
As of February 2024, Spero Therapeutics's annual revenue reached $18M.

What is Spero Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Spero Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Spero Therapeutics have currently?

Minus sign iconPlus sign icon
As of February 2024, Spero Therapeutics has approximately 65 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Operating Officer, Spero Therapeutics: T. K.Chief Financial Officer And Chief Business Officer: E. R.Chief Medical Officer: D. M.. Explore Spero Therapeutics's employee directory with LeadIQ.

What industry does Spero Therapeutics belong to?

Minus sign iconPlus sign icon
Spero Therapeutics operates in the Biotechnology Research industry.

What technology does Spero Therapeutics use?

Minus sign iconPlus sign icon
Spero Therapeutics's tech stack includes IBM Cognos AnalyticsDrupalGoogle ChartsprettyPhotoMicrosoftWebflowYoast SEONginx.

What is Spero Therapeutics's email format?

Minus sign iconPlus sign icon
Spero Therapeutics's email format typically follows the pattern of flast@sperotherapeutics.com. Find more Spero Therapeutics email formats with LeadIQ.

How much funding has Spero Therapeutics raised to date?

Minus sign iconPlus sign icon
As of February 2024, Spero Therapeutics has raised $9M in funding. The last funding round occurred on Sep 22, 2022.

When was Spero Therapeutics founded?

Minus sign iconPlus sign icon
Spero Therapeutics was founded in 2013.
Spero Therapeutics

Spero Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases. Spero’s lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Spero’s partnership directed programs consist of SPR206 and tebipenem HBr, which through the company’s business development efforts, have joint venture relationships supporting their ongoing development.  SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections, in the hospital setting.  Tebipenem HBr, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, or cUTIs, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. 
 

We believe that our novel product candidates will have a meaningful impact on patient health and significant commercial applications for treating MDR infections in hospitals and community settings. 

Section iconCompany Overview

Headquarters
675 Massachusetts Ave 14th Floor Cambridge, MA 02139 US
Phone number
+1-857-242-1600
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
SPRO
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
11-50

Section iconFunding & Financials

  • $9M

    Spero Therapeutics has raised a total of $9M of funding over 15 rounds. Their latest funding round was raised on Sep 22, 2022.

  • $10M$50M

    Spero Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $9M

    Spero Therapeutics has raised a total of $9M of funding over 15 rounds. Their latest funding round was raised on Sep 22, 2022.

  • $10M$50M

    Spero Therapeutics's revenue is in the range of $10M$50M

© LeadIQ, Inc. All rights reserved.